Lindén, O. et al. 2002. 131 I-labelled Anti-CD22 MAb (LL2) in Patients with B-Cell Lymphomas Failing Chemotherapy. Acta Oncologica. 41, 3 (Jan. 2002), 297–303. DOI:https://doi.org/10.1080/02841860260088854.